3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Colorectal Neoplasms
60
Neoplasms
41
Carcinoma, Non-Small-Cell Lung
32
Ovarian Neoplasms
27
Neoplasm Metastasis
22
Glioblastoma
19
Lung Neoplasms
17
Fallopian Tube Neoplasms
16
Colonic Neoplasms
16
Breast Neoplasms
16
Rectal Neoplasms
15
Pancreatic Neoplasms
15
Carcinoma, Renal Cell
13
Carcinoma, Hepatocellular
12
Stomach Neoplasms
10
Glioma
10
Carcinoma, Ovarian Epithelial
8
Solid Cancers
7
Sarcoma
7
Melanoma
7
Liver Neoplasms
7
Brain Neoplasms
7
Unspecified Adult Solid Tumor, Protocol Specific
6
Solid Tumors
6
Uterine Cervical Neoplasms
5
Recurrence
5
Lymphoma, Non-Hodgkin
5
Astrocytoma
5
Advanced Cancer
5
Triple Negative Breast Neoplasms
4
Interventions
vocimagene amiretrorepvec
1
enfortumab vedotin
1
catumaxomab
1
apatorsen
1
Ty21a typhoid vaccine
1
Therapeutics
1
Photochemotherapy
1
Paclitaxel
1
Mitomycin
1
Imiquimod
1
Gemcitabine
1
Flucytosine
1
Ethacrynic Acid
1
Bevacizumab
1
BCG Vaccine
1
Antibodies
1
1-phenyl-3,3-dimethyltriazene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Non-Muscle Invasive Bladder Neoplasms
×
Bevacizumab
×
Clear all
NCT06448364
2024-11-06
LTbR
Pfizer
Phase 1
Terminated
4 enrolled